Review Article

Drug Adherence, in Liver Transplant, Patients: A Review

ABSTRACT

Transplantation of liver due to liver failure provides the chance to patient to live in pleasant environment and improve their health-related quality of life. The therapeutic objectives of liver transplant only be achieved if the patient becomes adherent to the therapy prescribed by the doctors such as Immunosuppressant drugs and life style as suggested. Endurance of the liver transplant patients in the starting five years after the liver transplant varies from 60-80%. The survival depends upon type of illness which leads to liver transplantation the causative agents including comorbidities, carelessness in liver damaging diseases and fails to manage self-life care. The major risk after transplantation, are the organ dysfunction and the graft failure. Therefore, the outcomes of transplant will not be achieved if the patient become non adherent to therapy on the other hand cost will also increased. Non adherence can be determined by interaction with patients to know the different factors that involves in non-adherence such as health care system of the patient, socio economic condition of the patient, availability of prescribed medicines, underlying disease and medical condition of the patient. Patient is said to be adherent if the patient taking 80-110% medicines according to prescription. In case of liver transplantation non adherence may vary from 2-67% and the annual average estimated as 35.6%, as a result graft rejection or failure in transplantation may occurs, cost of treatment may also increase and morbidity and mortality may also increase. There are different tools used to determine non adherence some of them are counting the number of tablets, self-reported questionnaire, reporting of common side effects of immunosuppressive drugs, determination of serum level of immunosuppressant drugs and electronic monitoring. Out of these methods the most common, easy and cost-effective method for assessing the non-adherence in medical practice is self-reporting. Self-reporting method is highly specific because the questionnaire used in this, contain specific questions it is also used with other tools to get the specific information of patient's medication use behavior. Medication Adherence among Liver Transplant Recipients can be improved by application of reminder approaches such as Phone Calls, Mobile Application

and/or Patient Counseling and medication non-adherence have negative impact on quality of life of patients.

Key Words: Liver Transplantation, Adherence, Non adherence

Introduction

1. Liver Transplant

A liver transfer is an activity that replaces a patient's unhealthy liver with an entire or halfway solid liver from someone else [1,2]. This article clarifies the current signs for liver transplantation, sorts of giver livers, the actual activity, and the immunosuppressant that is needed after transplantation [3-5].

1.1 Liver Anatomy and Function

The liver is a fundamental organ, implying that one can't live without it. The liver serves numerous basic capacities including digestion of medications and poisons, eliminating corruption results of ordinary body digestion (for instance freedom of smelling salts and bilirubin from the blood), and union of numerous significant proteins and chemicals, (for example, factors fundamental for blood to cluster) [6-9].

Blood enters the liver from two channels, the hepatic corridor and the gateway vein, carrying supplements and oxygen to liver cells, otherwise called hepatocytes, and bile conduits [10]. Blood leaves the liver by means of the hepatic veins which channel into the second-rate vena cava which promptly enters the heart [11,12]. The liver makes bile, a fluid that assists break down with fatting and kill metabolic waste and poisons by means of the digestive system. Each hepatocyte makes bile and discharges it into tiny channels that join to frame bile conduits. Like feeders joining to shape a stream, the bile conduits join to frame a solitary "hepatic pipe" that carries bile into the digestive system [13,14].



Fig. 1. Liver Anatomy

1.2 Who Needs a Liver Transplantation

Liver transplantation precisely replaces a weak or infected liver with one that is ordinary and sound. Right now, transplantation is the main remedy for liver inadequacy or liver disappointment in light of the fact that no gadget or machine dependably plays out every one of the elements of the liver. Individuals who require liver transfers ordinarily have one of the accompanying conditions [15-17].

1.2.1 Intense Liver Failure

Intense liver disappointment, otherwise called fulminant hepatic disappointment, happens when a formerly sound liver experiences huge injury bringing about clinical signs and side effects of liver deficiency. Quite a few things can prompt intense liver disappointment yet the most widely recognized causes are acetaminophen (Tylenol®) glut, viral contaminations (known or yet obscure infection), ingestion of a poison like noxious mushrooms, or a quirky medication response [18,19].

The sign of this condition is the advancement of disarray (encephalopathy) inside about two months after the beginning of yellowing of the skin (jaundice). Disarray happens on the grounds that poisons normally used by the liver aggregate. In contrast to patients with persistent liver illness, who can endure a long time to months to years while anticipating liver transplantation, patients with intense liver dysfunction might pass on in practically no time if not relocated.

These patients are recorded at most noteworthy need (Status I), setting them at the highest point of nearby, provincial and public sitting tight records for a contributor liver [20-23].

1.2.2 Persistent liver disappointment

The liver has a wonderful capacity to fix itself because of injury. By and by, rehashed injury and fix, regularly over numerous years and even many years, scars the liver for all time [24]. The end phase of scarring is named cirrhosis and relates to where the liver can at this point don't fix itself [25,26]. When an individual has cirrhosis, the person might start to give indications of lacking liver capacity. This is named "decompensated liver illness." Although prescriptions can diminish the manifestations brought about by the liver disappointment, liver transplantation addresses the main long-lasting fix [27].

1.3 Signs and Symptoms of Decompensated Liver Disease

1.3.1 Gastrointestinal dying:

As the liver turns out to be progressively scarred, the protection from entrance blood stream builds prompting expanded strain in the entryway venous framework. This entrance hypertension requires elective courses for blood to get back to the heart. Little veins all through the mid-region, however outside of the liver, then, at that point, become augmented and slight walled due to the strangely high measure of blood coursing through them under expanded tension. These delicate veins, called varices, regularly line parts of the gastrointestinal parcel, particularly the throat and the stomach, and are inclined to burst and dying. When draining happens into the digestive system, it tends to be hazardous [28,29].

1.3.2 Fluid maintenance:

One capacity of the liver is to orchestrate large numbers of the proteins flowing in the circulation system, including albumin. Egg whites and different proteins in the circulation system hold liquid in the vascular space by applying what is known as an oncotic (or osmotic) pressure. In liver disappointment, low egg whites levels power liquid out of the circulatory system, which can't be re-assimilated. Liquid in this manner aggregates in tissues and body cavities, most regularly, in the stomach depression, which is named "ascites." Fluid can likewise collect in the legs (fringe or pedal edema), or in the chest pit (hydrothorax). Liquid maintenance is dealt with first by severe impediment of dietary salt admission, second with prescriptions (diuretics) that power expanded salt and water misfortune through the kidneys and, ultimately, by irregular seepage through addition of a needle into the stomach or chest pit [30,31].

1.3.3 Encephalopathy:

Failure of the liver to clean smelling salts and different poisons off of the blood permits these substances to aggregate. These toxin chemicals bring about intellectual brokenness that reaches from upset rest wake cycle examples to gentle disarray to extreme lethargies.

1.3.4 Jaundice:

One of the fundamental elements of the liver is to wipe out the debasement results of hemoglobin, the atom that conveys oxygen in our blood. Bilirubin is one of those corruption items prepared and discharged by the liver. In liver disappointment, bilirubin isn't cleared from the body and bilirubin levels increase in the blood. The skin and all tissues of the body will then, at that point, expect a yellow tone [32,33].

1.4 Reasons for Chronic Liver Injury

1.4.1 Viral Hepatitis

1.4.1.1 Hepatitis B:

Hepatitis B disease represents 5% of all liver transfers acted in the United States however represents a bigger extent of liver transfers in different areas of the planet, particularly Asia and Australia/New Zealand.

1.4.1.2 Hepatitis C:

This is the most widely recognized sign for liver transplantation in the United States, influencing almost half of all liver transfer beneficiaries.

1.4.2 Alcoholic Liver Disease

Liver disappointment because of liquor misuse is the second most normal sign for liver transplantation in the United States. Most focuses need no less than a six-month time of forbearance, regularly inside a perceived substance misuse program like Alcoholics Anonymous, as a state of posting for transplantation [34,35].

1.4.3 Metabolic Liver Disease

1.4.3.1 Non-alcoholic steatohepatitis (NASH): Deposition of fat inside liver cells might bring about irritation that harms and scars the liver. Hazard factors for the improvement of greasy liver and NASH incorporate corpulence and metabolic conditions like diabetes and hyperlipidemia (expanded cholesterol). The level of patients being relocated for this condition has expanded 35 overlap from 2000 to 2005 [36].

1.4.4 Immune system Liver Disease

Autoimmune hepatitis (annihilation of the liver by the patient's own safe framework), Cholestatic Liver Diseases, Primary Biliary Cirrhosis (PBC) (annihilation of little bile channels inside the liver), Primary Sclerosing Cholangitis (PSC) (obliteration of bile channels inside and outside the liver). Over two thirds of patients with PSC likewise experience the ill effects of ulcerative colitis, an immune system issue of the colon, Neonatal sclerosing cholangitis (contamination and scarring of the bile conduits in the liver of a baby), Biliary atresia (nonappearance of bile conduits outside the liver), Caroli's infection (irregularity of the bile conduits inside the liver), TPN-initiated cholestasis. Patients who get intravenous nourishment, named complete parenteral sustenance (TPN) at times foster bile balance (easing back or halting of typical bile stream) that can, after some time, lead to liver injury and disappointment[37,38].

1.4.5 Hereditary Liver Disease

Hemachromatosis: abundance iron statement in the liver, Wilson's illness: strange copper digestion, Alpha-1 enemy of trypsin insufficiency: absence of a quality item that restricts the movement of trypsin, a compound that digests protein. Over the long run this prompts reformist obliteration of the liver and lung, Glycogen stockpiling infection (type I, III, IV): an acquired metabolic issue, Tyrosinemia: a problem of tyrosine digestion [39].

1.4.6 Vascular Liver Disease

Budd-Chiari disorder is apoplexy (coagulating) of the hepatic veins which prompts helpless blood stream however the liver [40].

1.4.7 Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is an essential malignancy of the liver, implying that it begins from strange liver cells. HCC happens just infrequently in a typical, non-cirrhotic liver. Its rate is, in any case, strikingly expanded behind the scenes of cirrhosis and, specifically, by particular kinds of liver sickness that lead to cirrhosis (hepatitis B and C, hemachromatosis, and tyrosinemia) [41]. Albeit the malignancy initially begins inside the liver, as it develops it can spread to different organs, a cycle called metastasis. HCC most as often as possible spreads to the lungs or to bones. The danger of spread outside the liver increments, with the size of disease.

Liver transplantation conclusively fixes a patient of HCC, given that the growth has not spread past the liver. Since there are undeniably a bigger number of individuals needing liver transfers than there are accessible organs, explicit rules, called the Milan Criteria, have been set up to characterize which patients with HCC are qualified for transplantation. These standards

characterize cutoff points of growth number and size that guarantee an exceptionally low probability of malignancy spread outside of the liver [42].



Fig. 2. Hepatocellular Carcinoma

2. Adherence

Drug adherence, or taking prescriptions accurately, is for the most part characterized as the degree to which patients accept medicine as recommended by their primary care physicians. This includes factors, for example, getting solutions filled, making sure to take drug on schedule, and understanding the bearings [43]."

The American Medical Association says, "A patient is viewed as disciple in the event that they take 80% of their endorsed medicine(s). In the event that patients take under 80% of their recommended medication(s), they are considered non adherent." Solutions for a Healthy America states, "Prescription adherence happens when a patient takes their meds as per the endorsed measurement, time, recurrence, and bearing [44]."

The American Pharmacists Association says medicine adherence is "the degree to which a patient's conduct (e.g., taking prescriptions regarding timing, measurement, and recurrence) compares with settled upon suggestions from a medical care supplier [45]." At last, Pharmacy Times says drug adherence is "the degree to which patients accept prescriptions as recommended by their suppliers and settled upon in the treatment plan." Note: When characterizing medicine adherence, it is fundamental to recognize the term from prescription consistence. Peruse this examination of drug adherence and prescription consistence [46].

2.1 Prescription Adherence Challenges

Lamentably, there are a few obstructions to accomplishing prescription adherence, which all add to the disturbing results and insights shared toward the start of this blog. The following are four of the main difficulties:[47].

2.1.1 Capacity to pay for prescriptions

An ABC News report from April, referring to the consequences of an overview by Gallup and West Health, noticed that "Americans acquired $88 billion to pay for medical care in the beyond a year." Furthermore, the study showed that "15 million Americans conceded buying doctor prescribed medications because of the expenses of the drugs [48]."

Much later, information distributed in JAMA Open Network tracked down that high-deductible wellbeing plans, which are normal for managers, are making generous trouble for patients to keep up with adherence [49].

2.1.2 Low wellbeing education

The Center for Health Care Strategies expresses that "Almost 36% of grown-ups in the United States have low wellbeing education," with wellbeing proficiency characterized as "… how much people have the ability to get, measure, and comprehend essential wellbeing data and administrations expected to settle on fitting wellbeing choices [50]."

Restricted wellbeing proficiency is related with medicine nonadherence (not withstanding a huge number of other health and monetary difficulties). At the point when patients can't get a handle on basic ideas, like how to fill a prescription, how to take a medicine, when to take a drug, the amount of a prescription to take, and when and how to reorder a prescription, accomplishing and afterward keeping up with adherence turns out to be undeniably challenging, if certainly feasible [51].

2.1.3 Incidental effects

At the point when patients experience antagonistic incidental effects from taking meds, they are more disposed to quit taking meds or attempt to change their routine all alone to counter the impacts. There are a wide range of impacts liable to add to nonadherence. A survey directed by Health Dialog found that weight gain, queasiness/agitated stomach, dazedness/exhaustion, and skin disturbance were all instances of such bad incidental effects [52].

2.1.4 Polypharmacy

Patients taking something like five drugs commonly alluded to as polypharmacy face a few difficulties straightforwardly connected to this big number of remedies. These incorporate the Pcomplex dosing plan, guidance disarray, numerous incidental effects, and more prominent costs. To find out with regards to these and different snags, read our blog examining polypharmacy challenges [53].

The uplifting news for clinicians is that there are steps they can take to accomplish upgrades in understanding drug adherence. A fundamental advance is to set aside the effort to comprehend the reasons for non-adherence, for example, those examined previously. Finding out with regards to these causes will assist clinicians with bettering distinguish when such causes are probably going to add to non-adherence [54].

Giving schooling to patients is additionally crucial. At the point when patients better comprehend issues like the significance of following a drug routine and dangers of digressing from it, how to react to bothersome incidental effects, what to do in the event that they experience snags to adherence (e.g., managing the cost of meds, filling and reordering remedies), and how to get questions concerning their meds responded to sooner rather than later, adherence will improve. As a Patient Preference and Adherence study surveying the impact of various methods of patient instruction taking drugs adherence in patients with rheumatoid joint pain expressed in its decision, "Patient training altogether further develops adherence." Considering the critical job that cost can play in adding to nonadherence, clinicians should realize how to assist patients with beating this impediment. As we noted in a blog on quiet drug the board, "Cost should consistently be a theme covered by clinicians while talking about intercession regimens with patients. Likewise, clinicians should be ready to give assets to assist patients with lessening their prescription expenses. Such assets can remember data for how to acquire monetary help, securely request meds via mail, and recognize and utilize a favored drug store [55]."

One organization that is having an effect in this space is Good prescription, which we included in Our Favorite Healthcare Mobile Apps of 2019 post. Good Rx has been standing out as truly newsworthy for its remedy markdown application. The organization reports that the application has saved 10 million or more customers more than $14 billion starting around 2011 [56]. At last, clinicians ought to investigate the accessibility of devices and innovation that can help them in assisting their patients with keeping up with adherence. One such model is Cureatr's answer, the Meds 360° innovation stage. By giving clinicians admittance to ongoing endorsing and drug

store get data, they gain the capacity to distinguish potential prescription aversion practices and afterward address these issues before nonadherence negatively affects a patient's prosperity. Medications 360° is an asset clinicians and associations cross country are finding significant in their endeavors to give protected, great consideration that likewise adds to cost decrease and better accomplishes the targets of significant worth based medical services [57].

2.2 Measurement of adherence in Liver Transplant Patients

2.2.1 Direct Measures

Direct measures incorporate estimation of the medication or its metabolite fixation in body liquids, for example, blood or urine and assessment of the presence of a natural marker given with the medication and direct perception of patient's drug taking conduct. These actions can be made arbitrarily or at explicit spans [57].

Despite the fact that immediate measures are viewed as the most dependable and can be utilized as an actual proof to demonstrate that the patient has taken the drug, there are numerous downsides in regards to their utilization. They essentially create a Yes/No outcome without uncovering any example of the non-adherence or their causes [57-59]. Tests themselves can likewise be extremely meddlesome which might cause tension and uneasiness in patients.

Medication digestion ought to be considered while thinking about utilizing these strategies. For example, hints of neuroleptic and mental drugs can be distinguished in the blood even long subsequent to halting the prescription. Since people shift in physiological state and metabolic rate, drug plasma levels additionally vary after various people take a similar portion of a similar medication. Also, the actual evaluation can be troublesome. For example, riboflavin, a natural marker, is essentially non-quantitative for identification [45]. Furthermore, drug-drug collaborations and medication food connections can ruin the measure's precision. Subsequently, these immediate strategies are for the most part unsatisfactory for mental patients and those under multidrug systems, in any event, when they are hospitalized. Furthermore, direct measures are costly and difficult to implement since they require a large num ber of professionals and experts to check interactions and conduct testing. Patients can conceal th eir pills under their tongue and dispose of them via direct perception, making routine evaluation unnecessary. As a result, these activities are most commonly used for patients who are hospitalis ed and receiving single-portion treatment or discontinuous organization [35].

Patients can also develop an inclination if they take the drug right before their upcoming examin

ations.White coat adherence [29, 44] is a miracle that should not be missed in any study that incl udes direct metrics or medical calibre visits.

2.2.1.1 Measures Involving Secondary Database Analysis

The information of optional data set incorporates the arrangements and examples got from the curated essential information in frameworks, for example, electronic remedy administration or drug store protection guarantee. Such information permits evaluation of drug adherence to different top off adherence measures. Reorder adherence accepts that medicine topping off designs relate to the patient drug taking conduct. This supposition has been considered as an OK gauge [51]. Moreover, these actions likewise accept that the medicine is taken precisely as endorsed [49]. Therefore, fractional adherence where patients just partake in the prescription in that span can't be uncovered utilizing these actions.

To collect a comprehensive dataset during the assigned term, evaluating medicine top off records necessitates a concentrated electronic framework as well as consistency among prescribers and c ontainers. This allows for the analysis of a large population, resulting in the widespread use of thi s technique in research. This technique can also be used to assess multidrug adherence and identi fy patients who are at risk of treatment failure. Despite the fact that impediments, such as section highlights, can be measured and pinpointed as nonadherence variables, this technique doesn't pr ovide much information to the analyst or health specialists about the impediments associated wit h recognized nonadherence [50].

Managerial datasets arranging charging data for medical care administration and protection claim s are frequently used in research to avoid blunders from offbase information input, as this total d ataset, which includes every single remedy movement, is confirmed by insurance agencies or sol ution advantage chiefs (pbms) in the United States. The creators stated that scientists should rem ember to "separate treatment suspension from patient passing or switches in protection plans" an d to "verify the constant patient's qualification to participate." Furthermore, experts should be aw are that some opportunities may be missed if the right answer is not found [52].

2.2.1.2 Drug Possession Ratio (DPR)

MPR was defined by Andrade et al. As the number of days' stock gained over either a top off stre tch, where the last top off is the end point, or a fixed top off, where a certain time span is establis hed [54]. The former is used for situations such as people with depression or HIV, whereas the la tter is typically used for evaluating infrequent pharmaceutical use, asthma or allergies, and so on

[51]. MPR is challenging to employ on a large population study because of the denominator vari ation. Fitting connection and normal would be necessary in the future to adapt to widely adheren ce esteems [50].It's a very simple estimating method that ignores reordering gaps and "the need f or constant therapy with several medicines" [55]. As a result, when using this method, erroneous adherence esteems are identified.

2.2.1.3 Dichotomous Variable

To distinguish adherence from nonadherence or adherence from midway adherence, this action n ecessitates a cutoff worth [37, 49]. It has lower affectability than the constant variable, most likel y because to the lack of a pharmacological justification for selecting the cutoff esteem [37]. This has a significant impact on the test results' affectability and specificity. Because of these dra wbacks, a few authors have advocated for the use of constant variable measurements in all cases, because they demonstrate superior consistency and force [57].

2.2.1.4 Continuous, Multiple Interval Measure of Medication Acquisition (CMA)

CMA is calculated as the total days' stock obtained throughout a series of stretches separated by absolute days from the beginning to the end of the time period under consideration. The overall a verage of all members' CMA calculates the adherence value for the evaluation period [50] and ev aluates the association between adherence and medication impact [49]. CMA and MPR, together with Continuous Multiple Interval Measure of Oversupply (CMOS) and Medication Refill Adher ence (MRA), according to Hess et al. [50], have indistinguishable adherence estimation power.

2.2.1.5 Continuous, Multiple Interval Measure of Medication Gaps (CMG)

To detect any time stretches without drug openness, CMG measures are obtained by partitioning the absolute number of days in treatment holes by the duration of the time-frame of interest [49]. Any negative value would be set to zero. It calculates nonadherence values for multiple periods while ignoring the possibility of an early top off or pack. If any excess is included, CMOS shoul d be used to adapt to oversupplies obtained from prior solution stretches in order to accommodat e any extra prescription within the time span [50].

2.2.1.6 Continuous, Single Interval Measure of Medication Acquisition (CSA)

The continuous stock obtained in every stretch during the entire days in the span is dictated by th e CSA [49]. When a patient has more than one top off each day or when the top off is close to th e day of fruition, predisposition occurs [50].

2.2.1.7 Continuous, Single Interval Measure of Medication Gaps (CSG)

The CSG defines time periods during which drug openness is not possible. It is calculated by div iding the number of days with little or no medicine by the total number of days in the span. CSG, like CSA, is better for temporary medication openness, such as in patients who only have one so lution and whose transient medication use is indicated by clinical results [49].

Electronic Medication Packaging (EMP) devicesrelated Measures"Adherencechecking gadgets i ntegrated into the packing of a physician,

recommended medicine," according to EMP. They share certain common elements when only a f ew options are available: I altering media suggestions to signal time for the next portion; (ii) com puterised shows; (iv) constant watching; and (v) criticism on adherence execution [57]. The prev alence of the aforesaid highlights in gadgets is positioned in diving demand.

Despite the fact that not all of these features are available on all devices, tracking compliance exe cution is critical for investigation and tailoring necessary interventions. In prescription adherence studies, the Medication Events Monitoring System (MEMS) is the most commonly used EMP device.

2.2.2 Medication Events Monitoring System (MEMS)

Despite the fact that various models have been developed over many years, the fundamental rule of this framework is that when the medicine is removed from the compartment, a microchip is in serted to record the time and date, indicating that the patient has taken that portion at that specific time [27,37,45].

In a few studies, this objective measure is usually extremely precise. It can tell you whether your nonadherence is irregular or consistent, or if you're taking a weird medicine, and it can give you t he number of daily servings in any fractional adherence situation. MEMS are more useful than bi ochemical and self-report measures because of these factors.

Furthermore, the risk of misdirection is smaller than when using pills because the patient must ac cess the compartment repeatedly while assuming they must dispose of the drug to ensure that the same "adherence" design is recorded. As a result, it is frequently used as a reference point for ap proving other adherence measures.

Despite the fact that additional effort is expected to create the false impression of adherence, ther e is no proof that the patient would not undertake it.

Patients may mistakenly activate the compartment without taking the drug, in addition to purpose ly deceiving the framework. This can lead to erroneous prescription adherence decisions.
The holder's bulk is also an impediment, causing patients to relocate the pill to another compartm ent or forget to bring the prescription with them when they go out [37,45].
Furthermore, the holder's presence alone may serve as a reminder to the patient that they are ther e. This has been linked to the occurrence of tension, stress, and physical complaints [37].
Although the precision of MEMS is undeniable, its lack of interest for large populations, such as clinical preliminary or routine use, is linked to high costs and the amount of assistance required [27,37,45,57].The equipment alone is pricey. With the risk of device failure due to silence, the ren tal of equipment and programming for data recovery, staff time, bed days, and the cost of enticin g patients to return the cap, MEMS investigations take a significant amount of resources to comp lete. In a recent publication, a total of USD$274 per patient was required to complete a 6-month study that measured treatment adherence in individuals with schizophrenia or schizoaffect ive disorder [45].
Other functional concerns mentioned by these creators included the difficulty of organising tops off with outpatient pharmacy stores and the need to empower patients for proper cap usage [45]. The incorrect use of the MEMS holder may result in erroneous nonadherent patient orders [36].

2.2.3 Pill Count

This elliptical goal metric counts the number of dosage units consumed between two scheduled a rrangements or centre visits. The adherence proportion would then be calculated by comparing th is amount to the absolute number of units obtained by the patient [37, 41].
The low cost and simplicity of this method contribute to its popularity. Whatever the case may b e, a few roadblocks have been identified.First and foremost, despite the fact that it may be used t o a variety of definitions, such as tablets, containers, and inhaled inhaler, this methodology is uns uitable for evaluating nondiscrete dosages or Pro re nata (prn) drugs [41].In addition, because thi s technique essentially uses the allocated date as the denominator of the circumstance, ignoring t he possibility of having surplus prescription, adherence underestimate is common. It is common for people with chronic illnesses to refill their prescriptions before they run out [41].Furthermore , the cutoff value for separating adherence and nonadherence in this case is determined arbitrarily [37]. This can lead to mistakes when determining a patient's adherence and comparing drug adhe rence between examinees.

Despite the fact that pill counting is based on a similar premise as MEMS, which is that the expu lsion of the dose unit is the same as taking the drug, pill counting does not provide a medicine-accepting example in the same manner that the latter does.

The removal of the appropriate amount of dose units from the compartment does not imply that t he patient is adhering to the dosing system consistently [58, 59].Aside from failing to depict the a dherence design, pill counting is also unable to discern its causes [37].Although pill counting has demonstrated to be more precise than other abstract techniques, MEMS has since overtaken pill counting as a reference standard for validating other adherence metrics [37].

2.2.4 Measures Involving Clinician Assessments and Self-Report

Many artists agree that these ethereal tactics are the most shakiest of all. By the way, their low cost, ease of use, and constant input have boosted their popularity in clinical practise [26,60,61]. They can be managed through structured meetings, online evaluatio ns, written surveys, voice response systems, and so forth. Furthermore, because of their flexibilit y and adaptability, these surveys can identify particular patient issues and design appropriate inte rvention [27].

Obviously, the disadvantages of such techniques should not be overlooked. False information giv en by patients, either intentionally or accidentally [43,60], or defective relational abilities and qu estions generated by the questioners, similar to the plan of overview [37,45], can cause a sense of helplessness affectability and particularity. Antagonism in questioning, such as blaming patients for failing to meet their endorsed system's requirements, may lead to predisposition [37]. The me ntal condition of the patient can also influence the reaction [27]. As a result, such goal metrics ca n only pitifully predict patient adherence and are used more frequently in clinical practice than in research.

2.2.4.1 Patient-Kept Diaries

This is the major report device that is consistently archived with how the patient adheres to their prescribed system. However, erroneous judgement is extremely common, and a 30 percent overfl ow of journal passages has been shown to occur when contrasting and contrasting outcomes from MEMS data [37]. The failure to complete the evaluation if the patient does not return the journal or the detailed "false" increase in the patient's adherence rate from the observation stage to the s elf-appraisal stage [62] are also mentioned as factors that can complicate it.

2.2.4.2 Patient Interviews

Clinicians talking to patients is, for the most part, a low-cost, easy to use abstract technique for evaluating patient adherence [37]. Patients can be questioned about their prescription taking habits, such as the percentage of doses they miss in a certain time period or the frequency with which they fail to adhere to the medication regimen.

Questions, on the other hand, can be based on a thorough understanding of the individual's prescr ibed system, including medication names, schedules, and symptoms. Experts in medical services then examine their reaction to determine the degree of adherence.

However, the authors also stated that there is only limited proof of a link between a patient's info rmation on their medication system and true adherence [41]. Aside from the above mentioned traditional methods, inspiring meetings have grown in popularity in therapeutic practise. This co mbines the estimation of adherence and the ensuing intercession into a single instrument. It not o nly measures and assesses drug adherence, but it also intervenes in cases of prescription non-compliance.It was described by Mill operator and Rollnick as an instant patientfocused technique to help patients understand and overcome inner conflict in order to sup port social changes [63]. Originally meant to combat substance abuse, it is now aimed at identify ing patients' resistance to change and rousing them by counseling and addressing [64].

Rubak et al. Demonstrated in a metaanalysis that persuasive meeting outperforms traditional cou nsel giving in terms of combining distinguishing proof of the causes of nonadherence and resulti ng mediation [65].

2.2.4.3 Questionnaires and Scales

These abstract methodologies were first intended to limit the limits of other self-report techniques by normalizing the estimation of adherence to a particular medicine system [37]. These polls are by and large approved against different measures, both abstract and objective, and with various variants to oblige different conditions, for example, for a wide ran or single unhealthy populace, or in various dialects. Self-report polls ought to be finished by patients themselves or their overseers. In any case, polls can be hard for patients with low education levels [66].

In a methodical audit, Nguyen et al. Have recognized 43 approved self-report adherence scales, barring those that were not in English [60]. 40 out of these 43 scales have gauged the degree of execution of a dosing system, including the commencement, execution, and cessation stages. Besides, the creators classified the scales into 5 primary gatherings that assess the

accompanying: (I) just medicine taking practices; (ii) both prescription taking conduct and obstructions to adherence; (iii) just boundaries to adherence; (iv) just convictions related with drug adherence; and (v) the two hindrances to and convictions related with adherence. This survey characterized medicine accepting practices as any missing portion taken, just as recurrence on medicine top off while boundaries to adherence were characterized as inclination to neglect, illness explicit reasons, system intricacy, and additionally symptom of endorsed drugs. Convictions related with adherence are identified with individual worries on the prescription security or the need of following the endorsed system.

As far as deciding non-adherence, these creators summed up the procedure for those scales. Most investigated scales have a suggested cutoff esteem. Patients that took 80% or a greater amount of their drugs, as determined by a goal measure, for instance, MEMS, are accounted for as follower, and the people who took not exactly this cutoff esteem are accounted for as non-adherent, while some might compare to other self-report estimates that had been licensed by target gauges ahead of time. Aside from relationship with different measures, the examination of the adherence scale's mean scores of follower and non-adherent populaces can decide the cutoff esteem.

In the interim, a few scales, similar to the Medication Adherence Questionnaire (MAQ), the 8-thing Morisky Medication Adherence Scale (MMAS), and the Brief Medication Questionnaire, rank the level of adherence as opposed to characterizing a flat out cutoff for adherence. The reasoning of positioning can either be dictated by clinical results or scientist's mastery.

As many scales were recognized, this paper will zero in on those that are considered as the most valuable covering the idea of drug taking practices, hindrances to adherence, and conviction related with adherence.

2.2.4.3.1 Brief Medication Questionnaire

(BMQ stands for Belief about Medicines Questionnaire, therefore the Brief Medication Question naire isn't abbreviated as BMQ.) The Brief Medication Questionnaire looks into a patient's prescr iption-taking habits as well as potential barriers to adherence.

It is divided into three sections: a 5-item Regime screen, a 2-item Belief screen, and a 2-item Recall screen. These tests look at how patients took each of their medications in the past we ek, as well as drug adequacy, annoyances, and recollection issues.Svarstad et al. Went on to say t hat this survey is wellknown among medical services professionals because of its ability to allow self-organization, analyse multidrug regimens, and reduce expert preparation [37].

It was first offered for diabetes and discouragement, and it was advised that the executives and, p referably, the patients' recommended system be audited before being regulated. As a result, the e ntire interaction may be more cumbersome in comparison to other polls, making it difficult to ass ess at the point of care [36].

2.2.4.3.2 Hill-Bone Compliance Scale (Hill-Bone)

It has a limited generalizability as a proportion of evaluating patients' medicine-taking behaviour and barriers to adherence because it specifically targets individuals using hypert ension drugs. The test is scored on a four-point Likert

type scale and consists of three subscales: prescription taking behaviour, capacity to keep arrange ments, and sodium admission. The number of items available for testing varies depending on the population type. For metropolitan dark and local area abiding populations, 14-thing and 9-thing tests have been approved separately [36].

It has shown high inward consistency when first planned [45], as it did when used in an essential medical care setting in a review in South Africa [68]. Despite its great social affectability, the aut hors also claimed that Hill-Bone is better for black people than nonblack people [69].

In the meantime, a study of local residents showed that it had a high level of inward consistency i n outpatient settings [70]. As a result, this scale has been recognised as appropriate for use in hyp ertension screenings in a predominantly dark population.

7.3.3.3 Eight-Item Morisky Medication Adherence Scale (MMAS-8)

Morisky et al. Created this 8-thing (MMAS-8) in 2008 in response to the MAQ.

The first seven items are Yes/No responses, while the last item is a 5-point Likert response.

The extras revolve around drug, taking behaviours, particularly those associated with underuse, Such as distraction, allowing for a clearer recognition of adherence boundaries [66].While appro ving in "exceptionally poor pay minority patients treated for hypertension searching for routine c onsideration in a facility context" [61], 93 percent affectability and 53 percent explicitness were accounted for. In patients with other persistent illnesses, MMAS was also approved with surprisi ng validity and dependability [66].As a result, it is perhaps the most widely used selfreport meas ure of medication adherence.MMAS should be able to recognise drug nonadherence and assist w ith blood pressure control in addition to pulse control data [61]. It is prescribed to act as an assess ing device for acceptable conditions in the facility setting in this manner.

2.2.4.3.4 Medication Adherence Questionnaire (MAQ)

The Morisky Scale (MMAS-4) and the 4-thing Morisky Medication Adherence Scale (MMAS-4) are alternate names for the MAQ [26, 60, 66, 71]. Because of its length, this survey is the quic kest to direct and score, and it is simply ready to identify obstacles to adherence [26]. The closed inquiry design with the "yes,saying" tendency allows nonadherence to be revealed [66]. It is the most often used scale for research since it has been approved for the widest range of illnesses an d in individuals with minimal education [71].The coefficient alpha dependability of MAQ differe d among concentrations, just like legitimacy gauges, according to a review on factor construction and legitimacy of MAQ for cigarette smokers [72]. MAQ, in comparison to MMAS8, has more unfavourable psychometric features. Affectability and explicitness were 81 percent and 44 perce nt, respectively, in the first approval for hypertensive patients [73]. As a result, MMAS8 has bec ome more well-known than MAQ.

2.2.4.3.5 The Self-Efficacy for Appropriate Medication Use Scale (SEAMS)

The SEAMS is a 13-item, 3-point Likert-type scale that assesses self
adequacy across the board while calculating medication adherence barriers. Due to its length, it may be difficult to complete at the place of care. In any case, this scale has been approved for us e in a variety of current situations [26, 71].

The inner consistency of this scale was used to determine its dependability. SEAMS is a good sel f,report instrument for evaluating treatment adherence in persistent infections across the board, w ith coefficient alpha dependability of 0.89 and 0.88 on low and high proficiency populations, res pectively [26].

2.2.4.3.6 Medication Adherence Report Scale (MARS)

MARS assesses the two types of beliefs and barriers to medication adherence [60]. The Drug Att itude Inventory (DAI), a common mental adherence research, determines this. It hopes to reduce DAI's deficiencies by joining MAQ's enquiries. As a result, it may examine drug,taking habits an d attitudes about prescriptions with greater legitimacy and unwavering quality. It consists of ten questions with a basic scoring system to measure the patient's adherence behaviour, drug disposit ion, and general infection prevention throughout the previous week [74].MARS' inner consistenc y reliability is a mess [26]. In any case, Thompson et al. demonstrated that, in contrast to DAI an d MAQ, this scale exhibits strong positive associations. It was designed and originally approved for schizophrenic patients [74]. As a result, this measure should only be used in individuals who have a persistent psychological maladjustment.

2.2.4.3.7 Choosing a Suitable Medication Adherence Measure

An ideal drug adherence measure should introduce minimal expense and be easy to use, simple to do, exceptionally solid, adaptable, and commonsense [35,37]. Nonetheless, there is no single measure that can satisfy this load of gold guidelines since each has its own disadvantages as depicted previously.

From a wide perspective, emotional and target measures are liked in clinical and research settings, individually, fundamentally because of cost viability proportions. Self-report surveys, which have a sensible prescient force, are more valuable in an occupied; asset restricted clinical setting with moderate to high education populace. Patient's meeting by clinicians is liked for low proficiency populace or goes about as a subordinate where patients have as of now been anticipated as low medicine adherers. Despite the fact that pill count is a goal measure, the requirements of staff and time have made it essentially utilized in routine clinical practice all things being equal. While adjusting precision and cost, drug store top off measures are more ideal for a huge examination populace than utilizing emps. In the interim, direct measures are only occasionally utilized since the nosiness and the expense are too high to be in any way acknowledged by the two patients and specialists.

2.2.4.3.8 Multimeasure Approach

Multimeasure approach is regularly suggested in estimating prescription adherence. Since there is no ideal prescription adherence measure, it is fitting to utilize more than one measure when scientists mean to have results that are near the real world. Choosing (at least two) medicine adherence measures may permit qualities of one technique to assist with repaying putative shortcoming and to all the more precisely catch the data expected to decide adherence levels. A review utilizing this methodology which estimated the adherence to HIV protease inhibitors in 2001, Liu et al. Showed that the composite utilization of MEMS, pill count, and clinician's meeting held the most grounded prescient force contrasted with the force when each action was utilized independently [75].

A singular device can just distinguish patients with low to direct even out of adherence. Different variables, for example, white coat adherence, can prompt a mixed signal of prescription adherence. The utilization of a subsequent measure would then be able to assist with affirming the first discoveries. For example, despite the fact that MEMS is known for its high exactness, adherence misjudgment might in any case happen when utilizing this technique. Consequently, a

few investigations utilize different measures notwithstanding MEMS, for example, pill count, to authenticate the outcome and limit disparities [58,59].

Also, unique measure can recognize various parts of nonadherence. Emotional measures are more valuable in deciding the convictions and hindrances to adherence or foreseeing nonadherence. Target measures give more exact information on how patients act in their prescription systems. A straightforward self-report study has been utilized to foresee the event of low drug store tops off in a high-hazard older populace to further develop hypertensive administration [59]. A meta-investigation additionally showed that this methodology, including utilizing a self-report technique other than clinical record surveys alone, can expand the affectability for nonadherence [76]. The associative utilization of both evenhanded and abstract estimates will, in this way, give higher dependability and uncover more reasons of nonadherence, even in patients with undeniable degrees of adherence, and is as of now suggested [77].

In any case, expanded intricacy for examination and understanding ought to be recognized when utilizing a multimeasure approach, for example, unique time periods for estimations and various outcomes created [78]. In the interim, utilizing different measures with similar wellsprings of mistake, like two abstract measures, doesn't assist with foreseeing adherence level [79]. The expense and common sense of this methodology in clinical setting may likewise be a block. In this manner, while picking which measures ought to be incorporated, analysts should take likely mistakes, capacity to beat the point of reference hindrances, and reasonableness to be acted in the objective populace into thought.

2.3 Strategies For Improving Drug Adherence

A significant degree of comprehension is needed by the patient for this:

Optimum relational abilities should be utilized. Apart from routine advising drug specialist should give extra data to fill in the holes in understanding after the patient's interview with the specialist. Along with verbal data composed data should be given. Written data should be in non-specialized language to make it promptly comprehended.

Medication Management should be carried out by using Compliance chart, Compliance aids.

Memory helped gadgets: There is wide scope of plans of memory help gadgets for tablets and containers. The standard on which they work is that compartments are utilized to hold portions, every compartment relating to time. Examples: 7-day pill coordinator, Automatic pill clock, Daily pill minder.

Drug adherence in liver transplantation can also be improved by simplifying drug regimens of liver transplant recipients. Review he drugs to check whether routine can be improved to make it simpler to oversee. For instance utilization of supported delivery measurement structure lessens dose recurrence.

Pill-out (foil and rankle pack tablet remover), Tablet smasher, Tablet remover are also used to improve drug adherence in liver transplant patients.

Preparing patients during inpatient recuperation how to take drugs, Helping patients to utilize prompting, Fitting prescription routine to patient's way of life, Suggesting update frameworks, Giving gadgets to getting sorted out prescriptions, Conduct guiding intercession, Giving adherence updates during facility visits, Lessening the intricacy of the drug routine, Clinical directing by a clinical drug specialist, Setting up adherence contracts with patients, Utilizing reports from electronic checking gadget as an input framework

Conclusion

In developing countries like Pakistan with lesser literacy rate and scarcity of resources, Non adherence among post liver transplant recipients may lead to serious consequences. Hence there is a dire need to improve medication adherence particularly among post liver transplant recipients. Medication Adherence among Liver Transplant Recipients can be improved by application of reminder approaches such as Phone Calls, Mobile Application and/or Patient Counseling and medication non-adherence have negative impact on quality of life of patients.

References

1. Askmayoexpert. Liver transplant. Mayo Clinic; 2017.
2. Liver transplant. American Liver Foundation. Https://liverfoundation.org/for-patients/about-the-liver/the-progression-of-liver-disease/liver-transplant/#what-you-should-know-about-liver-transplantation. Accessed Oct. 14, 2019.
3. Liver transplant. National Institute of Diabetes and Digestive and Kidney Diseases. Https://www.niddk.nih.gov/health-information/liver-disease/liver-transplant. Accessed Oct. 14, 2019.
4. Waiting for your transplant. UNOS Transplant Living. Https://transplantliving.org/before-the-transplant/waiting-for-your-transplant/. Accessed Oct. 14, 2019.
5. Busuttil RW, et al., eds. Donor selection and management. In: Transplantation of the Liver. 3rd ed. Saunders Elsevier; 2015. Https://www.clinicalkey.com. Accessed Oct, 14, 2019.

6. Side effects. UNOS Transplant Living. Https://transplantliving.org/after-the-transplant/preventing-rejection/side-effects/. Accessed Oct.14, 2019.
7. Dove LM, et al. Liver transplantation in adults: Patient selection and pretransplantation evaluation. Https://www.uptodate.com/contents/search. Accessed Oct. 14, 2019.
8. Bambha K, et al. Model for end-stage liver disease (MELD). Https://www.uptodate.com/contents/search. Accessed Oct. 14, 2019.
9. Cotler S. Living donor liver transplantation. Https://www.uptodate.com/contents/search. Accessed Oct. 14, 2019.
10. Schenck D, et al. Ethical analysis and policy recommendations regarding domino liver transplantation. Transplantation. 2018; doi:10.1097/TP.0000000000002095.
11. Kim WR, et al. OPTN/SRTR 2017 annual data report: Liver. American Journal of Transplantation. 2019; doi:10.1111/ajt.15276.
12. Pardo MC, et al., eds. Organ transplantation. In: Basics of Anesthesia. 7th ed. Elsevier; 2018. Https://www.clinicalkey.com. Accessed Oct. 15, 2019.
13. Rumack CM, et al., eds. Organ transplantation. In: Diagnostic Ultrasound. 5th ed. Elsevier; 2018. Https://www.clinicalkey.com. Accessed Oct. 15, 2019.
14. Preventing rejection. UNOS Transplant Living. Https://transplantliving.org/after-the-transplant/preventing-rejection/. Accessed Oct. 15, 2019.
15. Why join a support group. UNOS Transplant Living. Https://transplantliving.org/community/support-groups/. Accessed Oct. 15, 2019.
16. Liver transplant. Scientific Registry of Transplant Recipients. Http://www.srtr.org. Accessed Oct. 15, 2019.
17. Glorioso JM, et al. Pivotal preclinical trial of the spheroid reservoir bioartificial liver. Journal of Hepatology. 2015; doi:10.1016/j.jhep.2015.03.021.
18. Yu Y, et al. Cell therapies for liver diseases. Liver Transplantation. 2012; doi:10.1002/lt.22467.
19. Taner T, et al. Decreased chronic cellular and antibody-mediated injury in the kidney following simultaneous liver-kidney transplantation. Kidney International. 2016; doi:10.1016/j.kint.2015.10.016.
20. De Assuncao TM, et al. Development and characterization of human-induced pluripotent stem cell-derived cholangiocytes. Laboratory Investigation. 2015; doi:10.1038/labinvest.2015.51.
21. Croome KP, et al. The use of donation after cardiac death allografts does not increase recurrence of hepatocellular carcinoma. American Journal of Transplantation. 2015; doi:10.1111/ajt.13306.
22. Find a transplant hospital. UNOS Transplant Living. Https://transplantliving.org/before-the-transplant/find-transplant-hospital/. Accessed Oct. 15, 2019.

23. E. Sabaté, *Adherence to Long-Term Therapies: Evidence for Action*, World Health Organization, Geneva, Switzerland, 2003.
24. M. T. Brown and J. K. Bussell, "Medication adherence: WHO cares?" *Mayo Clinic Proceedings*, vol. 86, no. 4, pp. 304–314, 2011.View at: Publisher Site | Google Scholar
25. M. J. Johnson, M. Williams, and E. S. Marshall, "Adherent and nonadherent medication-taking in elderly hypertensive patients," *Clinical Nursing Research*, vol. 8, no. 4, pp. 318–335, 1999.View at: Publisher Site | Google Scholar
26. S. M. Lavsa, A. Holzworth, and N. T. Ansani, "Selection of a validated scale for measuring medication adherence," *Journal of the American Pharmacists Association*, vol. 51, no. 1, pp. 90–94, 2011.View at: Publisher Site | Google Scholar
27. B. L. Svarstad, B. A. Chewning, B. L. Sleath, and C. Claesson, "The brief medication questionnaire: a tool for screening patient adherence and barriers to adherence," *Patient Education & Counseling*, vol. 37, no. 2, pp. 113–124, 1999.View at: Publisher Site | Google Scholar
28. P. J. Mcdonnell, M. R. Jacobs, H. A. Monsanto, and J.-M. Kaiser, "Hospital admissions resulting from preventable adverse drug reactions," *Annals of Pharmacotherapy*, vol. 36, no. 9, pp. 1331–1336, 2002.View at: Publisher Site | Google Scholar
29. L. Osterberg and T. Blaschke, "Adherence to medication," *The New England Journal of Medicine*, vol. 353, no. 5, pp. 487–497, 2005.View at: Publisher Site | Google Scholar
30. B. Vrijens, S. De Geest, D. A. Hughes et al., "A new taxonomy for describing and defining adherence to medications," *British Journal of Clinical Pharmacology*, vol. 73, no. 5, pp. 691–705, 2012.View at: Publisher Site | Google Scholar
31. M. A. Fischer, M. R. Stedman, J. Lii et al., "Primary medication non-adherence: analysis of 195,930 electronic prescriptions," *Journal of General Internal Medicine*, vol. 25, no. 4, pp. 284–290, 2010.View at: Publisher Site | Google Scholar
32. M. D. Solomon and S. R. Majumdar, "Primary non-adherence of medications: lifting the veil on prescription-filling behaviors," *Journal of General Internal Medicine*, vol. 25, no. 4, pp. 280–281, 2010.View at: Publisher Site | Google Scholar
33. E. Lehane and G. Mccarthy, "Medication non-adherence—exploring the conceptual mire," *International Journal of Nursing Practice*, vol. 15, no. 1, pp. 25–31, 2009.View at: Publisher Site | Google Scholar
34. D. L. Sackett, R. B. Haynes, and E. S. Gibson, "Patient compliance with antihypertensive regimens," *Patient Counselling and Health Education*, vol. 1, no. 1, pp. 18–21, 1978.View at: Publisher Site | Google Scholar

35. E. Vermeire, H. Hearnshaw, P. Van Royen, and J. Denekens, "Patient adherence to treatment: three decades of research. A comprehensive review," *Journal of Clinical Pharmacy and Therapeutics*, vol. 26, no. 5, pp. 331–342, 2001.View at: Publisher Site | Google Scholar
36. J. F. Steiner and M. A. Earnest, "The language of medication-taking," *Annals of Internal Medicine*, vol. 132, no. 11, pp. 926–930, 2000.View at: Publisher Site | Google Scholar
37. K. C. Farmer, "Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice," *Clinical Therapeutics*, vol. 21, no. 6, pp. 1074–1090, 1999.View at: Publisher Site | Google Scholar
38. F. Hurley, J. Cramer, and B. Spilker, "Statistical approach to subgroup analyses: patient compliance data and clinical outcomes," in *Patient Compliance in Medical Practice and Clinical Trials*, pp. 243–250, Raven Press, 1991.View at: Google Scholar
39. M. Z. Vitolins, C. S. Rand, S. R. Rapp, P. M. Ribisl, and M. A. Sevick, "Measuring adherence to behavioral and medical interventions," *Controlled Clinical Trials*, vol. 21, no. 5, supplement, pp. 188S–194S, 2000.View at: Google Scholar
40. D. I. Velligan, M. Wang, P. Diamond et al., "Relationships among subjective and objective measures of adherence to oral antipsychotic medications," *Psychiatric Services*, vol. 58, no. 9, pp. 1187–1192, 2007.View at: Publisher Site | Google Scholar
41. S. A. Vik, C. J. Maxwell, and D. B. Hogan, "Measurement, correlates, and health outcomes of medication adherence among seniors," *Annals of Pharmacotherapy*, vol. 38, no. 2, pp. 303–312, 2004.View at: Publisher Site | Google Scholar
42. M. A. Dew, A. D. Dabbs, L. Myaskovsky et al., "Meta-analysis of medical regimen adherence outcomes in pediatric solid organ transplantation," *Transplantation*, vol. 88, no. 5, pp. 736–746, 2009.View at: Publisher Site | Google Scholar
43. P. M. Ho, C. L. Bryson, and J. S. Rumsfeld, "Medication adherence: its importance in cardiovascular outcomes," *Circulation*, vol. 119, no. 23, pp. 3028–3035, 2009.View at: Publisher Site | Google Scholar
44. B. Jimmy and J. Jose, "Patient medication adherence: measures in daily practice," *Oman Medical Journal*, vol. 26, no. 3, pp. 155–159, 2011.View at: Publisher Site | Google Scholar
45. E. Diaz, H. B. Levine, M. C. Sullivan et al., "Use of the medication event monitoring system to estimate medication compliance in patients with schizophrenia," *Journal of Psychiatry and Neuroscience*, vol. 26, no. 4, pp. 325–329, 2001.View at: Google Scholar

46. J. A. Cramer, R. D. Scheyer, and R. H. Mattson, "Compliance declines between clinic visits," *Archives of Internal Medicine*, vol. 150, no. 7, pp. 1509–1510, 1990.View at: Publisher Site | Google Scholar
47. A. C. Modi, L. M. Ingerski, J. R. Rausch, T. A. Glauser, and D. Drotar, "White coat adherence over the first year of therapy in pediatric epilepsy," *The Journal of Pediatrics*, vol. 161, no. 4, pp. 695–699.e1, 2012.View at: Publisher Site | Google Scholar
48. R. S. Downie, *Clinical Judgement: Evidence in Practice*, edited by: J. Macnaughton, F. Randall, Oxford University Press, Oxford, UK, 2000.
49. J. F. Steiner and A. V. Prochazka, "The assessment of refill compliance using pharmacy records: methods, validity, and applications," *Journal of Clinical Epidemiology*, vol. 50, no. 1, pp. 105–116, 1997.View at: Publisher Site | Google Scholar
50. L. M. Hess, M. A. Raebel, D. A. Conner, and D. C. Malone, "Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures," *Annals of Pharmacotherapy*, vol. 40, no. 7-8, pp. 1280–1288, 2006.View at: Publisher Site | Google Scholar
51. J. Barner, *Medication Adherence: Focus on Secondary Database Analysis*, ISPOR Student Forum, 2010.
52. M. M. Kitahata, S. D. Reed, P. W. Dillingham et al., "Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death," *International Journal of STD and AIDS*, vol. 15, no. 12, pp. 803–810, 2004.View at: Publisher Site | Google Scholar
53. M. Krousel-Wood, E. Holt, C. Joyce et al., "Differences in cardiovascular disease risk when antihypertensive medication adherence is assessed by pharmacy fill versus self-report: the Cohort Study of Medication Adherence among Older Adults (cosmo)," *Journal of Hypertension*, vol. 33, no. 2, pp. 412–420, 2015.View at: Publisher Site | Google Scholar
54. S. E. Andrade, K. H. Kahler, F. Frech, and K. A. Chan, "Methods for evaluation of medication adherence and persistence using automated databases," *Pharmacoepidemiology and Drug Safety*, vol. 15, no. 8, pp. 565–574, 2006.View at: Publisher Site | Google Scholar
55. D. R. Vanderpoel, M. A. Hussein, T. Watson-Heidari, and A. Perry, "Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis," *Clinical Therapeutics*, vol. 26, no. 12, pp. 2066–2075, 2004.View at: Publisher Site | Google Scholar

56. M. R. Dimatteo, P. J. Giordani, H. S. Lepper, and T. W. Croghan, "Patient adherence and medical treatment outcomes: a meta-analysis," *Medical Care*, vol. 40, no. 9, pp. 794–811, 2002.View at: Publisher Site | Google Scholar
57. K. D. Checchi, K. F. Huybrechts, J. Avorn, and A. S. Kesselheim, "Electronic medication packaging devices and medication adherence: a systematic review," *The Journal of the American Medical Association*, vol. 312, no. 12, pp. 1237–1247, 2014.View at: Publisher Site | Google Scholar
58. H. A. W. Van Onzenoort, W. J. Verberk, A. G. H. Kessels et al., "Assessing medication adherence simultaneously by electronic monitoring and pill count in patients with mild-to-moderate hypertension," *The American Journal of Hypertension*, vol. 23, no. 2, pp. 149–154, 2010.View at: Publisher Site | Google Scholar
59. J. Y. Lee, J. W. Kusek, P. G. Greene et al., "Assessing medication adherence by pill count and electronic monitoring in the African American study of kidney disease and hypertension (AASK) pilot study," *American Journal of Hypertension*, vol. 9, no. 8, pp. 719–725, 1996.View at: Publisher Site | Google Scholar
60. T.-M. Nguyen, A. L. Caze, and N. Cottrell, "What are validated self-report adherence scales really measuring?: a systematic review," *British Journal of Clinical Pharmacology*, vol. 77, no. 3, pp. 427–445, 2014.View at: Publisher Site | Google Scholar
61. D. E. Morisky, A. Ang, M. Krousel-Wood, and H. J. Ward, "Predictive validity of a medication adherence measure in an outpatient setting," *Journal of Clinical Hypertension*, vol. 10, no. 5, pp. 348–354, 2008.View at: Publisher Site | Google Scholar
62. R. J. Straka, J. T. Fish, S. R. Benson, and J. T. Suh, "Patient self-reporting of compliance does not correspond with electronic monitoring: an evaluation using isosorbide dinitrate as a model drug," *Pharmacotherapy*, vol. 17, no. 1, pp. 126–132, 1997.View at: Google Scholar
63. W. R. Miller and S. Rollnick, *Motivational Interviewing: Preparing People to Change Addictive Behavior*, Guilford Press, 1991.
64. J. Kavookjian, "Motivational interviewing," in *PSAP-VII Book 8 (Science and Practice of Pharmacotherapy)*, American College of Clinical Pharmacy, Lenexa, Kan, USA, 2011.View at: Google Scholar
65. S. Rubak, A. Sandbæk, T. Lauritzen, and B. Christensen, "Motivational interviewing: a systematic review and meta-analysis," *British Journal of General Practice*, vol. 55, no. 513, pp. 305–312, 2005.View at: Google Scholar

66. X. Tan, I. Patel, and J. Chang, “Review of the four item Morisky Medication Adherence Scale (MMAS-4) and eight item Morisky Medication Adherence Scale (MMAS-8),” *Innovations in Pharmacy*, vol. 5, no. 3, p. 165, 2014.View at: Google Scholar
67. M. T. Kim, M. N. Hill, L. R. Bone, and D. M. Levine, “Development and testing of the Hill-Bone Compliance to High Blood Pressure Therapy Scale,” *Progress in cardiovascular nursing*, vol. 15, no. 3, pp. 90–96, 2000.View at: Publisher Site | Google Scholar
68. E. V. Lambert, K. Steyn, S. Stender, N. Everage, J. M. Fourie, and M. Hill, “Cross-cultural validation of the hill-bone compliance to high blood pressure therapy scale in a South African, primary healthcare setting,” *Ethnicity and Disease*, vol. 16, no. 1, pp. 286–291, 2006.View at: Google Scholar
69. M. Krousel-Wood, C. Joyce, E. W. Holt et al., “Development and evaluation of a self-report tool to predict low pharmacy refill adherence in elderly patients with uncontrolled hypertension,” *Pharmacotherapy*, vol. 33, no. 8, pp. 798–811, 2013.View at: Publisher Site | Google Scholar
70. M. Krousel-Wood, P. Muntner, A. Jannu, K. Desalvo, and R. N. Re, “Reliability of a medication adherence measure in an outpatient setting,” *The American Journal of the Medical Sciences*, vol. 330, no. 3, pp. 128–133, 2005.View at: Publisher Site | Google Scholar
71. J. Culig and M. Leppée, “From Morisky to Hill-bone; self-reports scales for measuring adherence to medication,” *Collegium Antropologicum*, vol. 38, no. 1, pp. 55–62, 2014.View at: Google Scholar
72. B. A. Toll, S. A. Mckee, D. J. Martin, P. Jatlow, and S. S. O'Malley, “Factor structure and validity of the Medication Adherence Questionnaire (MAQ) with cigarette smokers trying to quit,” *Nicotine and Tobacco Research*, vol. 9, no. 5, pp. 597–605, 2007.View at: Publisher Site | Google Scholar
73. D. E. Morisky, L. W. Green, and D. M. Levine, “Concurrent and predictive validity of a self-reported measure of medication adherence,” *Medical Care*, vol. 24, no. 1, pp. 67–74, 1986.View at: Publisher Site | Google Scholar
74. K. Thompson, J. Kulkarni, and A. A. Sergejew, “Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses,” *Schizophrenia Research*, vol. 42, no. 3, pp. 241–247, 2000.View at: Publisher Site | Google Scholar

75. H. Liu, C. E. Golin, L. G. Miller et al., "A comparison study of multiple measures of adherence to HIV protease inhibitors," *Annals of Internal Medicine*, vol. 134, no. 10, pp. 968–977, 2001.View at: Publisher Site | Google Scholar
76. H. Bosworth, *Improving Patient Treatment Adherence: A Clinician's Guide*, Springer, New York, NY, USA, 2010.
77. M. A. Rapoff, *Adherence to Pediatric Medical Regimens*, Issues in Clinical Child Psychology, Springer, New York, NY, USA, 2nd edition, 2010.
78. A. C. Modi, C. S. Lim, N. Yu, D. Geller, M. H. Wagner, and A. L. Quittner, "A multi-method assessment of treatment adherence for children with cystic fibrosis," *Journal of Cystic Fibrosis*, vol. 5, no. 3, pp. 177–185, 2006.View at: Publisher Site | Google Scholar
79. M. M. Llabre, K. E. Weaver, R. E. Durán, M. H. Antoni, S. Mcpherson-Baker, and N. Schneiderman, "A measurement model of medication adherence to highly active antiretroviral therapy and its relation to viral load in HIV-positive adults," *AIDS Patient Care and stds*, vol. 20, no. 10, pp. 701–711, 2006.View at: Publisher Site | Google Scholar